Flecainide Is Associated With a Lower Incidence of Arrhythmic Events in a Large Cohort of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia.
Auke T BergemanKrystien V V LieveDania KallasJ Martijn BosFerran Roses Y NoguerIsabelle DenjoyEsther Zorio-GrimaJanneke A E KammeraadPuck J PeltenburgKathryn E TobertTakeshi AibaJoseph AtallahFabrizio DragoAnjan S BatraRamón BrugadaMartin BorggrefeSally-Ann B ClurMoniek G P J CoxAndrew M DavisSantokh S DhillonSusan P EtheridgePeter FischbachSonia FranciosiKristina Hermann HaugaaMinoru HorieChristopher JohnsrudeAustin M KaneUlrich KrauseSit-Yee KwokMartin J LaPageSeiko OhnoVincent ProbstJason D RobertsTomas RobynsFrédéric SacherChristopher SemsarianJonathan R SkinnerHeikki SwanTerezia TavacovaSvjetlana Tisma-DupanovicJacob Tfelt HansenSing-Chien YapPrince J KannankerilAntoine LeenhardtJanice TillShubhayan SanataniMichael W T TanckMichael J AckermanArthur A M WildeChristian van der WerfPublished in: Circulation (2023)
For patients with catecholaminergic polymorphic ventricular tachycardia, adding flecainide to beta-blocker therapy was associated with a lower incidence of AEs in the overall cohort, in symptomatic patients, and particularly in patients with breakthrough AEs while on beta-blocker therapy.